Effectiveness and safety of systemic cyclosporine for high-risk keratoplasty

Masahiro Omoto, Shigeto Shimmura, Murat Dogru, Jun Shimazaki, Kazuo Tsubota

Research output: Contribution to journalArticle

Abstract

We reviewed 51 high-risk eyes of 50 patients receiving penetrating keratoplasty. They were given systemic cyclosporine A to prevent immune graft rejection. High risk was defined as the presence of corneal neovascularization in 2 or more quadrants or repeat keratoplasty. During follow-up for an average of 14.9 ± 10.2 months, the graft remained transparent in 37 eyes (73%). Allograft rejection developed in 13 eyes (26%). As temporary side effects, hiccups, abdominal pain, systemic hypertension, mental confusion, and dysuria developed in one patient each. The findings show that systemic cyclosporine A is safe and effective in preventing immune graft rejection if protocol is strictly adhered to.

Original languageEnglish
Pages (from-to)773-776
Number of pages4
JournalJapanese Journal of Clinical Ophthalmology
Volume58
Issue number5
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Corneal Transplantation
Cyclosporine
Graft Rejection
Safety
Hiccup
Corneal Neovascularization
Dysuria
Penetrating Keratoplasty
Abdominal Pain
Allografts
Hypertension
Transplants

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effectiveness and safety of systemic cyclosporine for high-risk keratoplasty. / Omoto, Masahiro; Shimmura, Shigeto; Dogru, Murat; Shimazaki, Jun; Tsubota, Kazuo.

In: Japanese Journal of Clinical Ophthalmology, Vol. 58, No. 5, 2004, p. 773-776.

Research output: Contribution to journalArticle

@article{cf05ab6c83fb4d75935c66bdd21e010f,
title = "Effectiveness and safety of systemic cyclosporine for high-risk keratoplasty",
abstract = "We reviewed 51 high-risk eyes of 50 patients receiving penetrating keratoplasty. They were given systemic cyclosporine A to prevent immune graft rejection. High risk was defined as the presence of corneal neovascularization in 2 or more quadrants or repeat keratoplasty. During follow-up for an average of 14.9 ± 10.2 months, the graft remained transparent in 37 eyes (73{\%}). Allograft rejection developed in 13 eyes (26{\%}). As temporary side effects, hiccups, abdominal pain, systemic hypertension, mental confusion, and dysuria developed in one patient each. The findings show that systemic cyclosporine A is safe and effective in preventing immune graft rejection if protocol is strictly adhered to.",
author = "Masahiro Omoto and Shigeto Shimmura and Murat Dogru and Jun Shimazaki and Kazuo Tsubota",
year = "2004",
language = "English",
volume = "58",
pages = "773--776",
journal = "Japanese Journal of Clinical Ophthalmology",
issn = "0370-5579",
publisher = "Igaku-Shoin Ltd",
number = "5",

}

TY - JOUR

T1 - Effectiveness and safety of systemic cyclosporine for high-risk keratoplasty

AU - Omoto, Masahiro

AU - Shimmura, Shigeto

AU - Dogru, Murat

AU - Shimazaki, Jun

AU - Tsubota, Kazuo

PY - 2004

Y1 - 2004

N2 - We reviewed 51 high-risk eyes of 50 patients receiving penetrating keratoplasty. They were given systemic cyclosporine A to prevent immune graft rejection. High risk was defined as the presence of corneal neovascularization in 2 or more quadrants or repeat keratoplasty. During follow-up for an average of 14.9 ± 10.2 months, the graft remained transparent in 37 eyes (73%). Allograft rejection developed in 13 eyes (26%). As temporary side effects, hiccups, abdominal pain, systemic hypertension, mental confusion, and dysuria developed in one patient each. The findings show that systemic cyclosporine A is safe and effective in preventing immune graft rejection if protocol is strictly adhered to.

AB - We reviewed 51 high-risk eyes of 50 patients receiving penetrating keratoplasty. They were given systemic cyclosporine A to prevent immune graft rejection. High risk was defined as the presence of corneal neovascularization in 2 or more quadrants or repeat keratoplasty. During follow-up for an average of 14.9 ± 10.2 months, the graft remained transparent in 37 eyes (73%). Allograft rejection developed in 13 eyes (26%). As temporary side effects, hiccups, abdominal pain, systemic hypertension, mental confusion, and dysuria developed in one patient each. The findings show that systemic cyclosporine A is safe and effective in preventing immune graft rejection if protocol is strictly adhered to.

UR - http://www.scopus.com/inward/record.url?scp=3042544651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042544651&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:3042544651

VL - 58

SP - 773

EP - 776

JO - Japanese Journal of Clinical Ophthalmology

JF - Japanese Journal of Clinical Ophthalmology

SN - 0370-5579

IS - 5

ER -